Demographic, clinical, and survival data for 349 adults with ALL
| . | Total, n (%) . | Sex ratio, M/F . | Age . | WCC* . | Outcome† . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treated, n (%) . | CR rate, n (%)‡ . | Deaths, n (%)§ . | OS at 5 years‖ . | ||||||||
| Mean . | Older than 60 y, % . | Median . | More than 50, % . | OS, % . | 95% CI, % . | ||||||
| Total (full dataset) | 349 | 1:0.9 | 46.4 | 36 | 13.6 | 20 | 250 (72) | 194 (70) | 177 (73) | 30 | (24- 36) |
| Successful cytogenetics | |||||||||||
| Total | 236 | 1:0.8 | 45.4 | 34 | 14.6 | 20 | 177 (75) | 133 (75) | 126 (71) | 29 | (22- 37) |
| t(9;22)(q34;q11) | 36 (15) | 1:0.6 | 50.6 | 39 | 30.1 | 42 | 26 (72) | 17 (65) | 24 (92) | 9 | (2- 26) |
| t(4;11)(q21;q23) | 10 (4) | 1:1.5 | 39.1 | 10 | 43.6 | 50 | 9 (90) | 7 (78) | 6 (67) | 33 (at 3 years) | (8-62) |
| t(1;19)(q23;p13) | 6 (3) | 1:5 | 33.2 | 21.5 | 16 | 6 (100) | 6 (100) | 3 (50) | 60 | (13- 88) | |
| t(8;14)(q24;q32) | 17 (7) | 1:0.9 | 60.8 | 59 | 15.7 | 6 | 10 (59) | 4 (44) | 8 (80) | 20 | (3%- 48%) |
| t(14;18)(q32;q21)¶ | 10 (4) | 1:0.8 | 60.0 | 67 | 20.0 | 16 | 5 (50) | 2 (40) | 4 (80) | 33 (at 1 year) | (1-77) |
| HeH# | 17 (7) | 1:0.5 | 33.9 | 18 | 3.1 | 6 | 15 (88) | 15 (100) | 5 (36) | 77 | (45-92) |
| HoTr‡‡ | 7 (3) | 1:1.3 | 55.1 | 86 | 2.6 | — | 6 (86) | 4 (67) | 6 (100) | 0 | — |
| Complex†† | 15 (7) | 1:0.5 | 58.9 | 60 | 13.0 | — | 5 (33) | 4 (80) | 4 (80) | 20 | (1- 58) |
| Other | 59 (25) | 1:0.8 | 42.2 | 29 | 16.3 | 24 | 48 (85) | 39 (81) | 34 (76) | 27 | (14-41) |
| Normal‡‡ | 62 (26) | 1:0.7 | 40.8 | 29 | 10.0 | 16 | 49 (79) | 35 (71) | 34 (69) | 32 | (18-46) |
| Cytogenetic risk group | |||||||||||
| t(9;22) | 36 (15) | 1:0.6 | 50.6 | 39 | 30.1 | 42 | 26 (72) | 17 (65) | 24 92% | 9 | (2-26) |
| Poor | 56 (24) | 1:1.3 | 55.8 | 52 | 15.2 | 13 | 33 (59) | 21 (66) | 26 79% | 19 | (7-36) |
| Standard | 144 (61) | 1:0.8 | 40.0 | 26 | 11.0 | 18 | 118 (82) | 95 (82) | 76 67% | 37 | (27-46) |
| . | Total, n (%) . | Sex ratio, M/F . | Age . | WCC* . | Outcome† . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treated, n (%) . | CR rate, n (%)‡ . | Deaths, n (%)§ . | OS at 5 years‖ . | ||||||||
| Mean . | Older than 60 y, % . | Median . | More than 50, % . | OS, % . | 95% CI, % . | ||||||
| Total (full dataset) | 349 | 1:0.9 | 46.4 | 36 | 13.6 | 20 | 250 (72) | 194 (70) | 177 (73) | 30 | (24- 36) |
| Successful cytogenetics | |||||||||||
| Total | 236 | 1:0.8 | 45.4 | 34 | 14.6 | 20 | 177 (75) | 133 (75) | 126 (71) | 29 | (22- 37) |
| t(9;22)(q34;q11) | 36 (15) | 1:0.6 | 50.6 | 39 | 30.1 | 42 | 26 (72) | 17 (65) | 24 (92) | 9 | (2- 26) |
| t(4;11)(q21;q23) | 10 (4) | 1:1.5 | 39.1 | 10 | 43.6 | 50 | 9 (90) | 7 (78) | 6 (67) | 33 (at 3 years) | (8-62) |
| t(1;19)(q23;p13) | 6 (3) | 1:5 | 33.2 | 21.5 | 16 | 6 (100) | 6 (100) | 3 (50) | 60 | (13- 88) | |
| t(8;14)(q24;q32) | 17 (7) | 1:0.9 | 60.8 | 59 | 15.7 | 6 | 10 (59) | 4 (44) | 8 (80) | 20 | (3%- 48%) |
| t(14;18)(q32;q21)¶ | 10 (4) | 1:0.8 | 60.0 | 67 | 20.0 | 16 | 5 (50) | 2 (40) | 4 (80) | 33 (at 1 year) | (1-77) |
| HeH# | 17 (7) | 1:0.5 | 33.9 | 18 | 3.1 | 6 | 15 (88) | 15 (100) | 5 (36) | 77 | (45-92) |
| HoTr‡‡ | 7 (3) | 1:1.3 | 55.1 | 86 | 2.6 | — | 6 (86) | 4 (67) | 6 (100) | 0 | — |
| Complex†† | 15 (7) | 1:0.5 | 58.9 | 60 | 13.0 | — | 5 (33) | 4 (80) | 4 (80) | 20 | (1- 58) |
| Other | 59 (25) | 1:0.8 | 42.2 | 29 | 16.3 | 24 | 48 (85) | 39 (81) | 34 (76) | 27 | (14-41) |
| Normal‡‡ | 62 (26) | 1:0.7 | 40.8 | 29 | 10.0 | 16 | 49 (79) | 35 (71) | 34 (69) | 32 | (18-46) |
| Cytogenetic risk group | |||||||||||
| t(9;22) | 36 (15) | 1:0.6 | 50.6 | 39 | 30.1 | 42 | 26 (72) | 17 (65) | 24 92% | 9 | (2-26) |
| Poor | 56 (24) | 1:1.3 | 55.8 | 52 | 15.2 | 13 | 33 (59) | 21 (66) | 26 79% | 19 | (7-36) |
| Standard | 144 (61) | 1:0.8 | 40.0 | 26 | 11.0 | 18 | 118 (82) | 95 (82) | 76 67% | 37 | (27-46) |
ALL indicates acute lymphoblastic leukemia; CI, confidence interval; CR, complete remission; HeH, high hyperdiploidy; HoTr, low hypodiploidy/near triploidy; OS, overall survival; and WCC, white cell count.
Information only available for 320 patients.
This only includes those 250 patients treated with curative intent.
CR only available for 247 patients.
Status unavailable for 16 patients.
OS information available for 234 patients as the result of missing data.
This chromosomal abnormality was expressed in conjunction with the t(8;14) in 3 patients
High hyperdiploidy (51-65 chromosomes).
Low hyperdiploidy (30-39 chromosomes)/near triploidy (60-78 chromosomes).
Complex karyotype defined as 5 or more chromosomal abnormalities in the absence of an established cytogenetic subgroup.
A total of 20 or more normal metaphases in the absence of any clonal chromosomal abnormality.